Company intelligence / Profile preview
Fortress Biotech
- Ownership
- Public · FBIO
- Development stage
- Other
Overview
Fortress Biotech is advancing several clinical programs, including a PDUFA goal date for CUTX-101 and commercial launches like Emrosi for rosacea. It has a diverse pipeline across multiple therapeutic areas.
- Therapeutic areas
- OncologyRare DiseasesDermatology
- Modalities
- Includes small molecules and biologics, though specific modalities are not detailed.
- Industry
- Biotech
Drug pipeline
8 assets7 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $61.4M
- Total revenue
- $63.3M
- Enterprise value
- $-70.4M
Beyond the preview
Go deeper on Fortress Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fortress Biotech.